Cargando…

SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy

Diabetic nephropathy (DN) is a major cause of end-stage renal disease (ESRD) worldwide. Glycemic and blood pressure (BP) control are important but not sufficient to attenuate the incidence and progression of DN. Sodium–glucose cotransporter (SGLT) 2 inhibitors are a new class of glucose-lowering age...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kawanami, Daiji, Matoba, Keiichiro, Takeda, Yusuke, Nagai, Yosuke, Akamine, Tomoyo, Yokota, Tamotsu, Sango, Kazunori, Utsunomiya, Kazunori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454992/ https://www.ncbi.nlm.nih.gov/pubmed/28524098 http://dx.doi.org/10.3390/ijms18051083

Ejemplares similares

Rho-Kinase Blockade Attenuates Podocyte Apoptosis by Inhibiting the Notch Signaling Pathway in Diabetic Nephropathy
por: Matoba, Keiichiro, et al.
Publicado: (2017)

ROCK2 Regulates Monocyte Migration and Cell to Cell Adhesion in Vascular Endothelial Cells
por: Takeda, Yusuke, et al.
Publicado: (2019)

ROCK Inhibition May Stop Diabetic Kidney Disease
por: Matoba, Keiichiro, et al.
Publicado: (2020)

Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence
por: Kawanami, Daiji, et al.
Publicado: (2016)

Unraveling the Role of Inflammation in the Pathogenesis of Diabetic Kidney Disease
por: Matoba, Keiichiro, et al.
Publicado: (2019)

The Physiology, Pathology, and Therapeutic Interventions for ROCK Isoforms in Diabetic Kidney Disease
por: Matoba, Keiichiro, et al.
Publicado: (2020)

Targeting Redox Imbalance as an Approach for Diabetic Kidney Disease
por: Matoba, Keiichiro, et al.
Publicado: (2020)

Endothelial Dysfunction in Diabetes
por: Takeda, Yusuke, et al.
Publicado: (2020)

ROCK2-induced metabolic rewiring in diabetic podocytopathy
por: Matoba, Keiichiro, et al.
Publicado: (2022)

Renal ROCK Activation and Its Pharmacological Inhibition in Patients With Diabetes
por: Matoba, Keiichiro, et al.
Publicado: (2021)

Efficacy of glucagon-like peptide-1 mimetics for neural regeneration
por: Sango, Kazunori, et al.
Publicado: (2015)

Hypoxia-inducible factor-1α is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy
por: Bessho, Ryoichi, et al.
Publicado: (2019)

Successful control of a case of severe insulin allergy with liraglutide
por: Kawanami, Daiji, et al.
Publicado: (2013)

Association between resistin and fibroblast growth factor 23 in patients with type 2 diabetes mellitus
por: Nakashima, Akio, et al.
Publicado: (2018)

SGLT2 Inhibitors: A Broad Impact Therapeutic Option for the Nephrologist
por: Granata, Antonio, et al.
Publicado: (2022)

Roles of α-Synuclein and Disease-Associated Factors in Drosophila Models of Parkinson’s Disease
por: Suzuki, Mari, et al.
Publicado: (2022)

Novel neuron-Schwann cell co-culture models to study peripheral nerve degeneration and regeneration
por: Sango, Kazunori
Publicado: (2022)

Effect of SGLT2 inhibitors on the proteinuria reduction in patients with IgA nephropathy
por: Dong, Yaping, et al.
Publicado: (2023)

264 Effective Reduction of Diabetic Nephropathy-Induced Albuminuria With SGLT2 inhibitor Monotherapy
Publicado: (2021)

Effect of One-Week Salt Restriction on Blood Pressure Variability in Hypertensive Patients with Type 2 Diabetes
por: Iuchi, Hiroyuki, et al.
Publicado: (2016)

Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors
por: Frąk, Weronika, et al.
Publicado: (2023)

Prospective randomized study for optimal insulin therapy in type 2 diabetic patients with secondary failure
por: Miyashita, Yumi, et al.
Publicado: (2008)

Unexpected Acute Hyperglycemia Following Pre-Surgical Discontinuation of SGLT2 Inhibitors in a Type 1 Diabetic Patient
por: Tsujimoto, Yuki, et al.
Publicado: (2023)

Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells
por: Maki, Toshinobu, et al.
Publicado: (2019)

Potential utility of aldose reductase-deficient Schwann cells IKARS1 for the study of axonal degeneration and regeneration
por: Niimi, Naoko, et al.
Publicado: (2018)

Zonisamide enhances neurite outgrowth from adult rat dorsal root ganglion neurons, but not proliferation or migration of Schwann cells
por: Takaku, Shizuka, et al.
Publicado: (2019)

Pretreatment with Zonisamide Mitigates Oxaliplatin-Induced Toxicity in Rat DRG Neurons and DRG Neuron–Schwann Cell Co-Cultures
por: Takaku, Shizuka, et al.
Publicado: (2022)

Renoprotective Effects of DPP-4 Inhibitors
por: Kawanami, Daiji, et al.
Publicado: (2021)

Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes
por: Matsutani, Daisuke, et al.
Publicado: (2018)

Thioglycosides as inhibitors of hSGLT1 and hSGLT2: Potential therapeutic agents for the control of hyperglycemia in diabetes
por: Castaneda, Francisco, et al.
Publicado: (2007)

SGLT2 inhibition to address the unmet needs in diabetic nephropathy
por: Barutta, Federica, et al.
Publicado: (2019)

SGLT Gene Expression in Primary Lung Cancers and Their Metastatic Lesions
por: Ishikawa, Nobuhisa, et al.
Publicado: (2001)

Visit-to-visit HbA1c variability is inversely related to baroreflex sensitivity independently of HbA1c value in type 2 diabetes
por: Matsutani, Daisuke, et al.
Publicado: (2018)

PSUN199 SGLT2-Inhibitor Prescription Rates in Individuals with Diabetic Nephropathy at a Teaching Outpatient Clinic
por: Abdulwahid, Tiba, et al.
Publicado: (2022)

GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms
por: Kawanami, Daiji, et al.
Publicado: (2020)

The Role of Bone-Derived Hormones in Glucose Metabolism, Diabetic Kidney Disease, and Cardiovascular Disorders
por: Takashi, Yuichi, et al.
Publicado: (2022)

Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice
por: Takahashi, Hiroyuki, et al.
Publicado: (2019)

Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2
por: Oranje, Paul, et al.
Publicado: (2019)

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
por: Vallianou, Natalia G., et al.
Publicado: (2021)

Basic and Clinical Pharmaco-Therapeutics of SGLT2 Inhibitors: A Contemporary Update
por: Kalra, Sanjay, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_varmis1cc7gea0n4leqlb3qj6t